comparemela.com

Latest Breaking News On - Enlivex therapeutics ltd stock exchange - Page 1 : comparemela.com

Enlivex Therapeutics : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 . | June 16, 2023

United statesTel avivState of israelDror mevorachHadassah university hospitalEnlivex therapeutics ltdCompany annual report on formCantor fitzgerald coIsraeli innovation authorityTel aviv stock exchangeContingent liabilitiesProfessor dror mevorachNasdaq capital marketTel aviv stockPrior yearFinancial accounting standards board

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Nes-Ziona, Israel, May 31, 2023 Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced three poster. | May 31, 2023

France generalShachar shlosbergerEnlivex therapeutics ltdInternational society for cell gene therapyExchange commissionElevator pitch presentationInternational societyGene therapyElevator pitch sessionHarbor statementPrivate securities litigation reform actAnnual reportEnlivex therapeutics ltd stock exchangePress releaseHree enlv il0011319527

Enlivex Receives Notice of Allowance for U S Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Nes-Ziona, Israel, April 19, 2023 Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced that the U.S. Patent. | April 19, 2023

United statesShachar shlosbergerEnlivex therapeutics ltdExchange commissionTrademark officeHarbor statementPrivate securities litigation reform actAnnual reportEnlivex therapeutics ltd stock exchangePress releaseHe enlv il0011319527

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Nes-Ziona, Israel, March 20, 2023 Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring. | March 20, 2023

Eric ribnerShachar shlosbergerEinat galamidiExchange commissionIsraeli ministry of healthEnlivex therapeutics ltdSafety monitoring boardIsraeli ministryMedical vice presidentHarbor statementPrivate securities litigation reform actAnnual reportEnlivex therapeutics ltd stock exchangePress releaseAfety enlv il0011319527

Enlivex Therapeutics : Report Of Foreign Private Issuer - Form 6-K

On December 30, 2022, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel , entered into an Agreement with Cantor Fitzgerald & Co. and JMP Securities LLC,. | December 30, 2022

United statesState of israelExchange commissionCantor fitzgerald coEnlivex therapeutics ltdCantor fitzgeraldOffered sharesSecurities actProspectus supplementNasdaq capital marketEnlivex therapeutics ltd stock exchangePress releaseEcurities enlv il0011319527

vimarsana © 2020. All Rights Reserved.